{"filing":{"accession_number":"0001776985-26-000047","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"form6-kxfgvariantvaccineec.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000047/form6-kxfgvariantvaccineec.htm"},"events":[{"id":21782,"run_id":19652,"accession_number":"0001776985-26-000047","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit announces European Commission authorization of an updated COVID-19 vaccine formula (XFG-adapted) for the 2026-2027 season. The disclosure is a regulatory milestone and product approval announcement that would materially affect investor assessment of BioNTech's commercial prospects and revenue potential from its COVID-19 vaccine franchise. While not fitting a discrete event category like M\u0026A or earnings, it represents a significant operational and commercial development—regulatory approval of a new vaccine variant formulation with anticipated supply and demand implications.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21506,"accession_number":"0001776985-26-000047","item_number":"EX-99.1","item_title":"a991covid-19xfgvariantecap.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces European Commission authorization of an updated COVID-19 vaccine formula (XFG-adapted) for the 2026-2027 season. The disclosure is a regulatory milestone and product approval announcement that would materially affect investor assessment of BioNTech's commercial prospects and revenue potential from its COVID-19 vaccine franchise. While not fitting a discrete event category like M\u0026A or earnings, it represents a significant operational and commercial development—regulatory approval of a new vaccine variant formulation with anticipated supply and demand implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:18:56.062146+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21506,"accession_number":"0001776985-26-000047","item_number":"EX-99.1","item_title":"a991covid-19xfgvariantecap.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces European Commission authorization of an updated COVID-19 vaccine formula (XFG-adapted) for the 2026-2027 season. The disclosure is a regulatory milestone and product approval announcement that would materially affect investor assessment of BioNTech's commercial prospects and revenue potential from its COVID-19 vaccine franchise. While not fitting a discrete event category like M\u0026A or earnings, it represents a significant operational and commercial development—regulatory approval of a new vaccine variant formulation with anticipated supply and demand implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:18:56.062146+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-07-29"}]}